Demyelinating diseases

Section edited by Francesco Patti and Tjalf Ziemssen

This section covers all types of demyelinating diseases. Topics of interest include, but are not limited to, multiple sclerosis, neuroimmunology, systemic lupus, vasculitis, lymphoma, and myelitis.

Previous Page Page 1 of 10 Next Page
  1. Case report

    Anti-MOG antibody-positive ADEM following infectious mononucleosis due to a primary EBV infection: a case report

    Anti-Myelin oligodendrocyte glycoprotein (MOG) antibodies are detected in various demyelinating diseases, such as pediatric acute disseminated encephalomyelitis (ADEM), recurrent optic neuritis, and aquaporin-...

    Yoshitsugu Nakamura, Hideto Nakajima, Hiroki Tani, Takafumi Hosokawa, Shimon Ishida, Fumiharu Kimura, Kimihiko Kaneko, Toshiyuki Takahashi and Ichiro Nakashima

    BMC Neurology 2017 17:76

    Published on: 19 April 2017

  2. Research article

    High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis – a randomized controlled trial

    People with multiple sclerosis have high risk of osteoporosis and fractures. A poor vitamin D status is a risk factor for MS, and vitamin D supplementation has been recommended both to prevent MS progression a...

    Trygve Holmøy, Jonas Christoffer Lindstrøm, Erik Fink Eriksen, Linn Hofsøy Steffensen and Margitta T. Kampman

    BMC Neurology 2017 17:67

    Published on: 4 April 2017

  3. Research article

    Healthcare resource use and costs of multiple sclerosis patients in Germany before and during fampridine treatment

    Multiple sclerosis (MS) patients often suffer from gait impairment and fampridine is indicated to medically improve walking ability in this population. Patient characteristics, healthcare resource use, and cos...

    Tjalf Ziemssen, Christine Prosser, Jennifer Scarlet Haas, Andrew Lee, Sebastian Braun, Pamela Landsman-Blumberg, Angela Kempel, Erika Gleißner, Sarita Patel and Ming-Yi Huang

    BMC Neurology 2017 17:62

    Published on: 27 March 2017

  4. Study protocol

    Protocol for a randomized, double blind, placebo controlled, crossover trial of Melatonin for treatment of Nocturia in adults with Multiple Sclerosis (MeNiMS)

    Nocturia (the symptom of needing to wake up to pass urine) is common in progressive Multiple Sclerosis (MS) patients. Moderate-to-severe nocturia affects quality of life, can exacerbate fatigue and may affect ...

    D. Delgado, L. Canham, N. Cotterill, D. Cottrell, M. J. Drake, K. Inglis, D. Owen and P. White

    BMC Neurology 2017 17:63

    Published on: 27 March 2017

  5. Research article

    Anxiety, emotional processing and depression in people with multiple sclerosis

    Despite the high comorbidity of anxiety and depression in people with multiple sclerosis (MS), little is known about their inter-relationships. Both involve emotional perturbations and the way in which emotion...

    Marie-Claire Gay, Catherine Bungener, Sarah Thomas, Pierre Vrignaud, Peter W Thomas, Roger Baker, Sébastien Montel, Olivier Heinzlef, Caroline Papeix, Rana Assouad and Michèle Montreuil

    BMC Neurology 2017 17:43

    Published on: 23 February 2017

  6. Case report

    Hashimoto’s encephalitis associated with AMPAR2 antibodies: a case report

    Hashimoto’s encephalitis (HE) is a rare neurological complication of Hashimoto’s thyroiditis (HT), while limbic encephalitis (LE) is an autoimmune inflammatory disorder frequently associated with anti-neuronal...

    Mingqin Zhu, Xuefan Yu, Caiyun Liu, Chenchen Duan, Chunxiao Li, Jie Zhu and Ying Zhang

    BMC Neurology 2017 17:37

    Published on: 21 February 2017

  7. Research article

    Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial

    Subcutaneous peginterferon beta-1a has previously been shown to reduce the number of T2-hyperintense and gadolinium-enhancing (Gd+) lesions over 2 years in patients with relapsing-remitting multiple sclerosis ...

    Douglas L. Arnold, Peter A. Calabresi, Bernd C. Kieseier, Shifang Liu, Xiaojun You, Damian Fiore and Serena Hung

    BMC Neurology 2017 17:29

    Published on: 10 February 2017

  8. Research article

    Long-term efficacy and safety of fingolimod in Japanese patients with relapsing multiple sclerosis: 3-year results of the phase 2 extension study

    The low level of disease activity and manageable safety profile seen with fingolimod versus placebo in a 6-month, phase 2, randomized controlled trial in Japanese patients with relapsing multiple sclerosis (MS...

    Takahiko Saida, Yasuto Itoyama, Seiji Kikuchi, Qi Hao, Takayoshi Kurosawa, Kengo Ueda, Lixin Zhang Auberson, Isao Tsumiyama, Kazuo Nagato and Jun-ichi Kira

    BMC Neurology 2017 17:17

    Published on: 28 January 2017

  9. Case report

    LETM presented with causalgia and ensued by sudden death

    Longitudinally Extensive Transverse Myelitis LETM is a specific pattern of myelitis wherein at least three continuous vertebral segments are involved. Characteristically, it is a defining feature of neuromyeli...

    Rana Alnasser Alsukhni, Yasmin Aboras, Ziena Jriekh, Mahmoud Almalla and Ahmad Sheikh El-Kahwateya

    BMC Neurology 2017 17:13

    Published on: 21 January 2017

  10. Research article

    Electrocardiographic assessments and cardiac events after fingolimod first dose – a comprehensive monitoring study

    First dose observation for cardiac effects is required for fingolimod, but recommendations on the extent vary. This study aims to assess cardiac safety of fingolimod first dose. Individual bradyarrhythmic epis...

    Volker Limmroth, Tjalf Ziemssen, Michael Lang, Stephan Richter, Bert Wagner, Judith Haas, Stephan Schmidt, Kathrin Gerbershagen, Christoph Lassek, Luisa Klotz, Olaf Hoffmann, Christian Albert, Katrin Schuh, Monika Baier-Ebert, Guillaume Wendt, Heinke Schieb…

    BMC Neurology 2017 17:11

    Published on: 18 January 2017

  11. Research article

    Subjective and objective assessment of physical activity in multiple sclerosis and their relation to health-related quality of life

    Physical activity (PA) is frequently restricted in people with multiple sclerosis (PwMS) and aiming to enhance PA is considered beneficial in this population. We here aimed to explore two standard methods (sub...

    Theresa Krüger, Janina R. Behrens, Anuschka Grobelny, Karen Otte, Sebastian Mansow-Model, Bastian Kayser, Judith Bellmann-Strobl, Alexander U. Brandt, Friedemann Paul and Tanja Schmitz-Hübsch

    BMC Neurology 2017 17:10

    Published on: 13 January 2017

  12. Research article

    Screening for onconeural antibodies in neuromyelitis optica spectrum disorders

    Some so-called “non-classical” paraneoplastic neurological syndromes (PNS), namely optic neuritis and myelitis, clinically overlap with neuromyelitis optica spectrum disorders (NMOSD), and conversely, in cance...

    Benjamin Berger, Tilman Hottenrott, Sebastian Rauer and Oliver Stich

    BMC Neurology 2017 17:5

    Published on: 10 January 2017

  13. Case report

    Anti-N-methyl-D-aspartate receptor(NMDAR) antibody encephalitis presents in atypical types and coexists with neuromyelitis optica spectrum disorder or neurosyphilis

    Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a clinically heterogeneous disorder characterized by epileptic seizures, psychosis, dyskinesia, consciousness impairments, and autonomic instability. ...

    Kaiyu Qin, Wenqing Wu, Yuming Huang, Dongmei Xu, Lei Zhang, Bowen Zheng, Meijuan Jiang, Cheng Kou, Junhua Gao, Wurong Li, Jinglin Zhang, Sumei Wang, Yanfei Luan, Chaoling Yan, Dan Xu and Xinmei Zheng

    BMC Neurology 2017 17:1

    Published on: 5 January 2017

  14. Research article

    Bone mineral density in patients with multiple sclerosis, hereditary ataxia or hereditary spastic paraplegia after at least 10 years of disease - a case control study

    Although disability is considered the main cause of low bone mineral density (BMD) in multiple sclerosis (MS), other factors related to the disease process or treatment could also be involved. The aim of this ...

    Cecilia Smith Simonsen, Elisabeth Gulowsen Celius, Cathrine Brunborg, Chantal Tallaksen, Erik Fink Eriksen, Trygve Holmøy and Stine Marit Moen

    BMC Neurology 2016 16:252

    Published on: 5 December 2016

  15. Research article

    A regional consensus recommendation on brain atrophy as an outcome measure in multiple sclerosis

    Multiple sclerosis (MS) is a chronic autoimmune disease characterized by inflammatory and neurodegenerative processes leading to irreversible neurological impairment. Brain atrophy occurs early in the course o...

    Raed Alroughani, Dirk Deleu, Khalid El Salem, Jasem Al-Hashel, K. John Alexander, Mohamed Assem Abdelrazek, Adel Aljishi, Jaber Alkhaboori, Faisal Al Azri, Nahida Al Zadjali, Majed Hbahbih, Tag Eldin Sokrab, Mohamed Said and Àlex Rovira

    BMC Neurology 2016 16:240

    Published on: 24 November 2016

Previous Page Page 1 of 10 Next Page

Can't find what you are looking for?

Articles for this section are still being added to this new-look site. In the meantime you can still view this section on our old site.